![Signaling pathways of chronic kidney diseases, implications for therapeutics | Signal Transduction and Targeted Therapy Signaling pathways of chronic kidney diseases, implications for therapeutics | Signal Transduction and Targeted Therapy](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41392-022-01036-5/MediaObjects/41392_2022_1036_Fig1_HTML.png)
Signaling pathways of chronic kidney diseases, implications for therapeutics | Signal Transduction and Targeted Therapy
Synthesis, Biological Evaluation, and Molecular Docking Study of 3-Amino and 3-Hydroxy-seco A Derivatives of α-Amyrin and 3-Epilupeol as Inhibitors of COX-2 Activity and NF-kB Activation | Journal of Natural Products
![Frontiers | Dissecting the Crosstalk Between Nrf2 and NF-κB Response Pathways in Drug-Induced Toxicity Frontiers | Dissecting the Crosstalk Between Nrf2 and NF-κB Response Pathways in Drug-Induced Toxicity](https://www.frontiersin.org/files/Articles/809952/fcell-09-809952-HTML/image_m/fcell-09-809952-g002.jpg)
Frontiers | Dissecting the Crosstalk Between Nrf2 and NF-κB Response Pathways in Drug-Induced Toxicity
![Figure 2 from Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties | Semantic Scholar Figure 2 from Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/10f0dd7b5611c76094720eb63c91db11d943e9a4/4-Figure2-1.png)
Figure 2 from Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties | Semantic Scholar
![APExBIO - Bardoxolone methyl|IKK inhibitor, potent antioxidant inflammation modulator|CAS# 218600-53-4 APExBIO - Bardoxolone methyl|IKK inhibitor, potent antioxidant inflammation modulator|CAS# 218600-53-4](http://www.apexbt.com/pub/media/prod_images/a/3/a3221.png)
APExBIO - Bardoxolone methyl|IKK inhibitor, potent antioxidant inflammation modulator|CAS# 218600-53-4
![Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells | Molecular Pharmacology Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells | Molecular Pharmacology](https://molpharm.aspetjournals.org/sites/default/files/highwire/molpharm/91/5.cover-source.jpg)
Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells | Molecular Pharmacology
![Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure | Journal of Pharmacology and Experimental Therapeutics Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/content/jpet/371/3/642/F2.large.jpg)
Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure | Journal of Pharmacology and Experimental Therapeutics
![Increased albuminuria in bardoxolone methyl–treated type 2 diabetes patients: mere reflection of eGFR improvement? - ScienceDirect Increased albuminuria in bardoxolone methyl–treated type 2 diabetes patients: mere reflection of eGFR improvement? - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0085253819306234-gr1.jpg)
Increased albuminuria in bardoxolone methyl–treated type 2 diabetes patients: mere reflection of eGFR improvement? - ScienceDirect
![Divulging the Intricacies of Crosstalk Between NF-Kb and Nrf2-Keap1 Pathway in Neurological Complications of COVID-19 | SpringerLink Divulging the Intricacies of Crosstalk Between NF-Kb and Nrf2-Keap1 Pathway in Neurological Complications of COVID-19 | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12035-021-02344-7/MediaObjects/12035_2021_2344_Fig6_HTML.png)
Divulging the Intricacies of Crosstalk Between NF-Kb and Nrf2-Keap1 Pathway in Neurological Complications of COVID-19 | SpringerLink
![Frontiers | Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages Frontiers | Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages](https://www.frontiersin.org/files/Articles/420947/fphar-09-01536-HTML/image_m/fphar-09-01536-g002.jpg)